Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-II TRIAL OF RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR IN METASTATIC SOFT-TISSUE SARCOMA
Autore:
MOMIN FA; ZALUPSKI M; HEILBRUN LK; FLAHERTY L; FYFE G; BAKER LH; REDMAN BG;
Indirizzi:
WAYNE STATE UNIV,HARPER HOSP,SCH MED,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,POB 02188 DETROIT MI 48201 WAYNE STATE UNIV,HARPER HOSP,SCH MED,DEPT INTERNAL MED,DIV HEMATOL & ONCOL DETROIT MI 48201 CHIRON CORP EMERYVILLE CA 94608
Titolo Testata:
Journal of immunotherapy with emphasis on tumor immunology
fascicolo: 3, volume: 16, anno: 1994,
pagine: 224 - 228
SICI:
1067-5582(1994)16:3<224:PTORHM>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR; C-FMS; RECEPTOR; CANCER; CSF-1;
Keywords:
RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR; SOFT TISSUE SARCOMA; LEIOMYOSARCOMA; ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; TUMOR NECROSIS FACTOR; INTERLEUKIN-1;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
16
Recensione:
Indirizzi per estratti:
Citazione:
F.A. Momin et al., "PHASE-II TRIAL OF RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR IN METASTATIC SOFT-TISSUE SARCOMA", Journal of immunotherapy with emphasis on tumor immunology, 16(3), 1994, pp. 224-228

Abstract

This Phase II study was undertaken to access the activity of recombinant human macrophage colony stimulating factor (M-CSF) in metastatic soft tissue sarcoma based on the observation of a partial response in apatient with leiomyosarcoma during an earlier Phase I trial. Fifteen patients with metastatic soft tissue sarcoma (seven males and eight females) were entered on the trial between October 1990 and March 1991. Seven of these patients had leiomyosarcoma. One mg/M(2) of M-CSF was administered by rapid intravenous infusion every 8 h on days 1-5 and 15-19. Treatment cycles were repeated at 35-day intervals. Patients wereevaluated initially for response after the first cycle, and then following alternate cycles. One partial response was observed in a patientwith metastatic small bowel leiomyosarcoma (response rate 7%, 95% confidence interval, 0-33%). Two additional patients had stable disease for 10-15 months on study. Four patients had clinically significant bleeding from tumor sites during M-CSF therapy. No evidence of toxicity directly attributable to M-CSF was observed in any patient. Mean monocyte counts increased in patients during the first 20 days of treatment (p = 0.013). At this dose and schedule, meaningful activity of M-CSF in previously treated patients with soft tissue sarcoma could not be demonstrated. However, the activity observed in patients with leiomyosarcoma in this trial and in the previous Phase I study are intriguing. Further studies of M-CSF in previously untreated patients with leiomyosarcoma may be warranted.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/07/20 alle ore 22:12:21